Gilead Sciences (NASDAQ:GILD) Earns “Neutral” Rating from Cantor Fitzgerald

Gilead Sciences (NASDAQ:GILD)‘s stock had its “neutral” rating reiterated by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $70.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential downside of 15.63% from the company’s previous close.

A number of other research firms also recently issued reports on GILD. Royal Bank of Canada increased their price target on shares of Gilead Sciences from $72.00 to $74.00 and gave the stock a “sector perform” rating in a research note on Wednesday, September 4th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Truist Financial increased their target price on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Finally, Robert W. Baird restated a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a research note on Thursday, June 20th. Twelve equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $82.06.

Gilead Sciences Trading Up 0.2 %

Shares of GILD stock traded up $0.16 during mid-day trading on Monday, reaching $82.97. The stock had a trading volume of 2,828,891 shares, compared to its average volume of 7,139,518. The firm has a market capitalization of $103.30 billion, a PE ratio of 230.47, a price-to-earnings-growth ratio of 2.80 and a beta of 0.18. The stock’s 50-day moving average price is $75.48 and its two-hundred day moving average price is $70.84. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. Gilead Sciences has a 52-week low of $62.07 and a 52-week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The company had revenue of $6.95 billion for the quarter, compared to the consensus estimate of $6.64 billion. Equities analysts expect that Gilead Sciences will post 3.78 earnings per share for the current fiscal year.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now directly owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares in the company, valued at approximately $8,506,146.42. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 36,847 shares of company stock worth $3,002,940. Insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. CarsonAllaria Wealth Management Ltd. lifted its position in shares of Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 238 shares during the last quarter. Sachetta LLC purchased a new stake in Gilead Sciences in the 4th quarter valued at about $30,000. Palisade Asset Management LLC purchased a new stake in shares of Gilead Sciences in the first quarter valued at approximately $29,000. Frank Rimerman Advisors LLC bought a new position in Gilead Sciences during the 4th quarter worth about $36,000. Finally, Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.